NCT00630695 is a Phase 3 clinical trial of Lanreotide LP 90 in Lymphocele, sponsored by University Hospital, Limoges.

Who is sponsoring NCT00630695?

NCT00630695 is sponsored by University Hospital, Limoges.

What drugs are being tested in NCT00630695?

Interventions in NCT00630695: Lanreotide LP 90, Placebo lanreotide.

What condition does NCT00630695 study?

NCT00630695 studies Lymphocele.

Is NCT00630695 still recruiting?

NCT00630695 is currently completed. Last updated 13 January 2012.

Last reviewed 2012-01-13 · How we verify

NCT00630695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer

Completed Phase 3 Last updated 13 January 2012

What this trial tests

Phase 3 trial testing Lanreotide LP 90 in Lymphocele in 148 participants. Completed in 1 December 2011.

Timeline

1 March 2008

Primary endpoint
1 June 2011

1 December 2011

Quick facts

Lead sponsor	University Hospital, Limoges
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	148
Start date	1 March 2008
Primary completion	1 June 2011
Estimated completion	1 December 2011
Sites	1 location across France

Drugs / interventions tested

Lanreotide LP 90 — full drug profile →
Placebo lanreotide — full drug profile →

Conditions studied

Lymphocele — all drugs for Lymphocele →

Sponsor

University Hospital, Limoges

Who can join

Adults 18 to 80, female only, with Lymphocele. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Quantity of lymph collected by the drain
Time frame: D4 post operativly

Sponsor's own description

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lymphocele

Currently open trials in the same condition.

NCT04819542 — Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles · NA · recruiting

Other University Hospital, Limoges trials

Trials by the same sponsor.

NCT07407101 — Impact of Filtration on Autologous Serum Eye Drops · NA · not yet recruiting
NCT07406425 — Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People. · NA · not yet recruiting
NCT07436780 — B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP · not yet recruiting
NCT07331298 — Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study · not yet recruiting
NCT07019818 — Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intu · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00630695 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Limoges
Last refreshed: 13 January 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00630695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing